Cryoport (NASDAQ:CYRX) Given Buy Rating at Roth Mkm

Cryoport (NASDAQ:CYRX)‘s stock had its “buy” rating reaffirmed by Roth Mkm in a research report issued on Tuesday,Benzinga reports. They currently have a $15.00 price target on the stock. Roth Mkm’s target price indicates a potential upside of 153.59% from the company’s current price.

A number of other research firms have also issued reports on CYRX. Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of Cryoport in a research report on Monday. UBS Group upped their price target on shares of Cryoport from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Guggenheim assumed coverage on shares of Cryoport in a research note on Thursday, December 19th. They set a “buy” rating and a $11.00 target price for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $11.83.

Cryoport Stock Performance

Shares of NASDAQ CYRX traded down $0.17 during trading on Tuesday, reaching $5.92. The stock had a trading volume of 283,639 shares, compared to its average volume of 536,374. The stock has a market cap of $295.22 million, a PE ratio of -1.76 and a beta of 1.67. The firm’s 50 day moving average price is $6.65 and its two-hundred day moving average price is $7.30. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. Cryoport has a one year low of $4.58 and a one year high of $20.11.

Cryoport (NASDAQ:CYRX) last issued its earnings results on Tuesday, March 4th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The company had revenue of $59.53 million during the quarter, compared to analyst estimates of $58.71 million. During the same quarter in the previous year, the firm earned ($0.29) earnings per share. On average, research analysts forecast that Cryoport will post -0.99 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Jerrell Shelton sold 4,620 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80. Following the completion of the sale, the chief executive officer now directly owns 765,399 shares in the company, valued at approximately $4,814,359.71. This trade represents a 0.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In the last three months, insiders have sold 19,830 shares of company stock worth $118,353. 10.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Cryoport

Institutional investors and hedge funds have recently modified their holdings of the stock. Cadian Capital Management LP grew its holdings in shares of Cryoport by 14.1% in the 4th quarter. Cadian Capital Management LP now owns 4,927,027 shares of the company’s stock worth $38,332,000 after acquiring an additional 609,021 shares during the last quarter. Millennium Management LLC increased its stake in Cryoport by 11.0% in the 4th quarter. Millennium Management LLC now owns 4,139,869 shares of the company’s stock valued at $32,208,000 after buying an additional 409,353 shares during the period. Deutsche Bank AG lifted its position in Cryoport by 0.9% in the 4th quarter. Deutsche Bank AG now owns 1,397,121 shares of the company’s stock worth $10,870,000 after buying an additional 12,864 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Cryoport by 3.6% in the third quarter. Geode Capital Management LLC now owns 1,097,369 shares of the company’s stock worth $8,902,000 after acquiring an additional 38,520 shares during the last quarter. Finally, State Street Corp boosted its position in Cryoport by 2.8% during the third quarter. State Street Corp now owns 1,003,080 shares of the company’s stock valued at $8,135,000 after purchasing an additional 27,438 shares during the last quarter. Institutional investors and hedge funds own 92.90% of the company’s stock.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.